Titan Pharmaceuticals - TTNP Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTNP, but not buy additional shares or sell existing shares.
View TTNP analyst ratings or view top-rated stocks.

Titan Pharmaceuticals' stock was trading at $1.02 at the beginning of 2022. Since then, TTNP shares have decreased by 20.4% and is now trading at $0.8120.
View the best growth stocks for 2022 here.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 1,779.72% and a negative trailing twelve-month return on equity of 183.12%.

Shares of Titan Pharmaceuticals reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Titan Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Truist Financial Corp (4.27%), Renaissance Technologies LLC (0.99%), State Street Corp (0.26%), Virtu Financial LLC (0.19%), FNY Investment Advisers LLC (0.19%) and Group One Trading L.P. (0.00%).
View institutional ownership trends.

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TTNP stock can currently be purchased for approximately $0.81.

Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $11.88 million and generates $1.53 million in revenue each year.

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.